The abstract is read at the publisher; the summary is JClub's.
OCE-205, a selective V1a mixed agonist-antagonist without V2 activity, was well tolerated in HRS-AKI, with bradycardia 21.6% and no ischemia or respiratory failure.
- Why it matters: Placebo-controlled evidence for new V1a-targeted therapies in hepatorenal syndrome–acute kidney injury is needed, but prior terlipressin approval limited trial feasibility.
- What they did: In a randomized, double-blind, placebo-controlled dose-ranging study at 23 North American centers, patients received continuous infusion of OCE-205 (8, 15, 30, or 50 µg/h) or placebo; primary endpoint was time to confirmed clinical improvement.
- The result: Confirmed clinical improvement occurred in 48.6% versus 30.0% (p=0.48 by Log-rank; NS by Bayesian analysis), suggesting capped maximal efficacy but leaving the study underpowered for significance.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.